WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels 2024

ATC codeATC level name
L02BX53abiraterone and prednisolone
B01AD13apadamtase alfa and cinaxadamtase alfa
C02KN01aprocitentan
P02BA03arpraziquantel
S01AA32bacitracin
C05XX01beperminogene perplasmid
D03AX16beremagene geperpavec
A10BK08bexagliflozin
N06AX62bupropion and dextromethorphan
B05XA19 1)calcium gluconate
L01EX27capivasertib
J01DE51cefepime and beta-lactamase inhibitor
J01DD58cefixime and beta-lactamase inhibitor
J01DC52cefuroxime and beta-lactamase inhibitor
C01CA28centhaquine
A01AB53chlorhexidine and cetylpyridinium
S01HA08chloroprocaine
C04AX33clazosentan
M04AC51colchicine and probenecid
B02BX10concizumab
J07BN05covid-19, virus-like particles
L04AJ07crovalimab
L04AJ09danicopan
N05CJ03daridorexant
L01BC58decitabine, combinations
M09AX15delandistrogene moxeparvovec
D11AH11delgocitinib
S01BA16difluprednate
L04AG15divozilimab
N06DX05donanemab
L03AA19eflapegrastim
L01XX79eflornithine
L02BA04elacestrant
A16AB26eladocagene exuparvovec
A05AX06elafibranor
J05AE16ensitrelvir
J07BX06enterovirus 71 vaccines
L01FX27epcoritamab
N07XX21eplontersen
A07FA03escherichia coli
B02BD16etranacogene dezaparvovec
L04AE05etrasimod
H05BX06evocalcet
B06AX05exagamglogene autotemcel
L01EK04fruquintinib
M09AX14givinostat
L01FX28glofitamab
N02AJ23hydrocodone and ibuprofen
N02AJ22hydrocodone and paracetamol
L01XX80imetelstat
A10AE07insulin icodec
L04AJ08iptacopan
A02BX16irsogladine
D11AH10lebrikizumab
N06DX04lecanemab
L03AX22leniolisib
A16AX23leriglitazone
L04AC25levilimab
L01XL11lifileucel
B01AC28limaprost
L01XL08lisocabtagene maraleucel
V04CX11lithium chloride
S01CA12loteprednol and antiinfectives
N02BA67magnesium salicylate, combinations excl. psycholeptics
A10BD28metformin and teneligliptin
L04AC24mirikizumab
L01FX26mirvetuximab soravtansine
L01EJ04momelotinib
L01FX25mosunetuzumab
L01XL10nadofaragene firadenovec
M01AE57naproxen and diphenhydramine
L01XX78navitoclax
D11AH12nemolizumab
L01XK52niraparib and abiraterone
C01CX10omecamtiv mecarbil
A02BC51omeprazole, combinations
L01EL04orelabrutinib
A16AB27pabinafusp alfa
H05AA05palopegteriparatide
S01XA31pegcetacoplan
C10AB12pemafibrate
N02AD51pentazocine and naloxone
C09BX06perindopril, bisoprolol, amlodipine and indapamide
C05AX06phenylephrine
L01EL05pirtobrutinib
S01AX24polihexanide
V03AB54pralidoxime and atropine
L01FY03prolgolimab and nurulimab
J05AP13ravidasvir
J07BX05respiratory syncytial virus vaccines
L04AF08ritlecitinib
B01AF51rivaroxaban and acetylsalicylic acid
D05AX06roflumilast
C10BX21rosuvastatin and perindopril
C10BX20rosuvastatin and telmisartan
L04AG16rozanolixizumab
R03AK15salbutamol and budesonide
L03AB17sampeginterferon beta-1a
L01FF12serplulimab
A10BD29sitagliptin and dapagliflozin
L01EX26sitravatinib
N07XX19sodium phenylbutyrate and ursodoxicoltaurine
G04BX17sodium salicylate and methenamine
B05XA20 2)sodium selenite
J05AR28stavudine and lamivudine
L01FF11sugemalimab
N02CC51sumatriptan and naproxen
L01XL09tabelecleucel
L01FX29talquetamab
D05AX07tapinarof
V09IA10technetium (99mTc) trofolastat chloride
L01FX24teclistamab
A10XX01teplizumab
N07XX22tofersen
L01FF13toripalimab
N07XX23troriluzole
A05AA05ursodoxicoltaurine
B02BD15valoctocogene roxaparvovec
H02AB18vamorolone
G04BD15vibegron
A02BD17vonoprazan and amoxicillin
L04AJ06zilucoplan
C09BX07zofenopril and nebivolol
1) Parenteral formulations should be classified here. Oral preparations should be classified in A12AA03.
2) Parenteral formulations should be classified here. Oral preparations should be classified in A12CE02.

Last updated: 2023-12-15